Document is current

Article History

Received: 5 September 2025

Accepted: 11 January 2026

First Online: 21 January 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethical Committee of the Ärztekammer Hamburg, Hamburg, Germany (PV5392). Informed consent was obtained from all subjects involved in the study.

: Not applicable.

: I.H. has received honoraria by BMS, and I.H. received honoraria from Sysmex for lectures/presentations outside the submitted work. J.K. has received honoraria from Bristol-Myers Squibb, UCB and Sanofi Genzyme and has received travel support from SUN Pharma and Pierre Fabre, outside the submitted work. G.G. has received honoraria by Almirall Hermal, BMS, SUN-Pharma, Janssen-Cilag, Mylan. G.G. has received travel expenses by MSD and SUN-Pharma. G.G has received grants from Regeneron Pharmaceuticals and Delcath Systems outside the submitted work. S.W.S. has received honoraria by GSK, Sanofi, Leo Pharma, Almirall and Pfizer. C.G. has received honoraria by BMS, GSK, Immunocore, MSD, Novartis, Pierre-Fabre, Sanofi, SUN-Pharma, Sysmex. C.G. has received travel expenses by BMS, Pierre-Fabre, SUN Pharma. C.G. is a member of the advisory board of BMS, Immuno-core, MSD, Novartis, Pierre-Fabre, Sanofi, SUN Pharma, Sysmex. C.G. is a board member of the DeCOG (ADO), unpaid; C.G. is a board member of the Hiege-Stiftung, unpaid. C.G. is board member of the Roggenbuck-Stiftung, unpaid. C.G. is founder of Dermagnostix and Dermagnostix R&D. K.P. received honoraria from Sysmex for lectures/presentations outside the submitted work. The other authors declare no conflict of interest.